27-Mar-2024
No headlines found.
Globe Newswire (Thu, 7-Mar 4:10 PM ET)
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Globe Newswire (Thu, 1-Feb 7:00 AM ET)
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 3-Jan 7:00 AM ET)
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Igm Biosciences trades on the NASDAQ stock market under the symbol IGMS.
As of March 27, 2024, IGMS stock price climbed to $9.27 with 261,744 million shares trading.
IGMS has a beta of 0.53, meaning it tends to be less sensitive to market movements. IGMS has a correlation of 0.00 to the broad based SPY ETF.
IGMS has a market cap of $544.95 million. This is considered a Small Cap stock.
Last quarter Igm Biosciences reported $651,000 in Revenue and -$1.01 earnings per share. This fell short of revenue expectation by $-49,000 and exceeded earnings estimates by $.02.
In the last 3 years, IGMS stock traded as high as $99.44 and as low as $3.81.
The top ETF exchange traded funds that IGMS belongs to (by Net Assets): VTI, VXF, IWM, IWN, SCHA.
IGMS has underperformed the market in the last year with a price return of -43.5% while the SPY ETF gained +33.6%. However, in the short term, IGMS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.2% vs +10.1% return in SPY. But in the last 2 weeks, IGMS shares have been beat by the market, returning -6.8% compared to an SPY return of +1.7%.
IGMS support price is $8.04 and resistance is $9.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IGMS stock will trade within this expected range on the day.